Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918019 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 517
- Enrollment target
NCT02918019 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 517 participants.
The verdict
NCT02918019, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 517 participants
- Enrollment target
Study Summary
This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following additional controller medications: long-acting beta-agonists (LABA), leukotriene modifier (LTM), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation. The total duration of this study for each participant is approximately 70 weeks including screening, run-in, treatment, and follow-up.
Interventions
- DRUG Placebo
- DRUG MSTT1041A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 517 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2019-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918019
The ClinicalTrials.gov registry entry for NCT02918019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 517 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02918019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02918019 about?
NCT02918019 is a clinical study titled "A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma". This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhal...
What is the current status of trial NCT02918019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 517 participants. The study started on 2016-09-20. Estimated completion is 2019-07-26.
What interventions are being tested in trial NCT02918019?
The interventions under investigation include: Placebo (DRUG), MSTT1041A (DRUG).
Who is sponsoring clinical trial NCT02918019?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.